Neil Woodford has added to a number of healthcare and biotech stocks in October in his £7.7bn Woodford Equity Income fund, despite continued weak performance from several stocks in the sector.
Healthcare stocks in the US have been suffering losses, following comments by Hilary Clinton about drug pricing, but Woodford (pictured) has continued to fervently defend the sector. Nonetheless, healthcare stocks have continued to struggle, with one of Woodford's holdings, BTG, being one of the main detractors from performance for the fund. Woodford defends healthcare amid ‘perverse' energy rally "BTG's half year results disappointed the market, primarily due to the slow adoption of Varithena, its treatment for varicose veins," the firm explained in its latest fund update. "This...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
